LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

11.37 -6.42

Resumen

Variación precio

24h

Actual

Mínimo

11.11

Máximo

11.6

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

110.024

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+62.95% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.26%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-120M

248M

Apertura anterior

17.79

Cierre anterior

11.37

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

141 / 351 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 feb 2026, 23:55 UTC

Charlas de Mercado

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Charlas de Mercado

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Charlas de Mercado

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Charlas de Mercado

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Charlas de Mercado

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Ganancias

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Ganancias

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Ganancias

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Ganancias

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Ganancias

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Ganancias

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Ganancias

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Ganancias

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Ganancias

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Ganancias

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Ganancias

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Ganancias

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Ganancias

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Ganancias

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Ganancias

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Adquisiciones, fusiones, absorciones

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Adquisiciones, fusiones, absorciones

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Ganancias

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Ganancias

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Charlas de Mercado

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Adquisiciones, fusiones, absorciones

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

62.95% repunte

Estimación a 12 Meses

Media 19 USD  62.95%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

141 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat